Drug Search Results
More Filters [+]

Levosulpiride

Alternative Names: levosulpiride
Latest Update: 2023-09-06
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: D2 Blocker

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral,Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Brazil | Bulgaria | Chile | Colombia | Cyprus | Dominican Republic | Ecuador | Egypt | India | Italy | Korea | Lebanon | Malta | Mexico | Pakistan | Peru | Portugal | Romania | Saudi Arabia | Spain | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Hainan Tianya Pharmaceutical Co., Ltd./Shanghai Huatuo Pharmaceutical Technology Development Co., Ltd./Hainan Sihuan Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Levosulpiride

Countries in Clinic: Unknown Location

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Depressive Disorder|Schizophrenia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20160303

P2

Not yet recruiting

Depressive Disorder|Schizophrenia

None

Recent News Events